Author:
Yamamoto Noboru,Horiike Atsushi,Fujisaka Yasuhito,Murakami Haruyasu,Shimoyama Tatsu,Yamada Yasuhide,Tamura Tomohide
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Cited by
72 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. In Vitro Assessment of Inhibitory Effects of Kinase Inhibitors on CYP2C9, 3A and 1A2: Prediction of Drug-Drug Interaction Risk with Warfarin and Direct Oral Anticoagulants;European Journal of Pharmaceutical Sciences;2024-08
2. Development and validation of a new liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of afatinib, dacomitinib, osimertinib, and the active metabolites of osimertinib in human serum;Journal of Chromatography B;2022-05
3. Application of a physiologically based pharmacokinetic model of rivaroxaban to prospective simulations of drug–drug–disease interactions with protein kinase inhibitors in cancer‐associated venous thromboembolism;British Journal of Clinical Pharmacology;2022-01-05
4. An Liquid Chromatography–Tandem Mass Spectrometry Method for the Simultaneous Determination of Afatinib, Alectinib, Ceritinib, Crizotinib, Dacomitinib, Erlotinib, Gefitinib, and Osimertinib in Human Serum;Therapeutic Drug Monitoring;2021-12
5. Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02;Neuro-Oncology Advances;2020-01-01